晚期胆管癌的新型靶向治疗
Novel Targeted Therapies for Advanced Cholangiocarcinoma.
作者信息
Rizzo Alessandro, Brandi Giovanni
机构信息
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, 40138 Bologna, Italy.
Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
出版信息
Medicina (Kaunas). 2021 Feb 26;57(3):212. doi: 10.3390/medicina57030212.
Abstract
Cholangiocarcinoma (CCA) includes a group of rare and aggressive hepatobiliary malignancies, including extrahepatic cholangiocarcinoma (eCCA) and intrahepatic cholangiocarcinoma (iCCA), with the former further subdivided into distal (dCCA) and perihilar cholangiocarcinoma (pCCA) [...].
摘要
胆管癌（CCA）包括一组罕见且侵袭性强的肝胆恶性肿瘤，包括肝外胆管癌（eCCA）和肝内胆管癌（iCCA），前者进一步细分为远端胆管癌（dCCA）和肝门周围胆管癌（pCCA）[...]。
相似文献
1
Novel Targeted Therapies for Advanced Cholangiocarcinoma.
Medicina (Kaunas). 2021 Feb 26;57(3):212. doi: 10.3390/medicina57030212.
2
Cholangiocarcinoma miscoding in hepatobiliary centres.
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
3
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
Medicina (Kaunas). 2021 Nov 27;57(12):1301. doi: 10.3390/medicina57121301.
4
The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
Recent Results Cancer Res. 2023;219:53-90. doi: 10.1007/978-3-031-35166-2_4.
5
Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Liver Int. 2019 May;39 Suppl 1:98-107. doi: 10.1111/liv.14086. Epub 2019 Mar 25.
6
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
7
Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
Liver Int. 2019 Feb;39(2):316-323. doi: 10.1111/liv.13954. Epub 2018 Oct 8.
8
Emerging molecular therapeutic targets for cholangiocarcinoma.
J Hepatol. 2017 Sep;67(3):632-644. doi: 10.1016/j.jhep.2017.03.026. Epub 2017 Apr 5.
9
[Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
Pathologe. 2020 Sep;41(5):488-494. doi: 10.1007/s00292-020-00808-6.
10
Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
Z Gastroenterol. 2024 Jan;62(1):37-42. doi: 10.1055/a-2207-5519. Epub 2024 Jan 9.
引用本文的文献
1
Cystic Duct Carcinoma: A New Classification System and the Clinicopathological Features of 62 Patients.
Front Oncol. 2021 Jun 11;11:696714. doi: 10.3389/fonc.2021.696714. eCollection 2021.
2
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Medicina (Kaunas). 2021 May 8;57(5):458. doi: 10.3390/medicina57050458.
本文引用的文献
1
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Cancers (Basel). 2021 Feb 1;13(3):558. doi: 10.3390/cancers13030558.
2
Immunotherapies in clinical development for biliary tract cancer.
Expert Opin Investig Drugs. 2021 Apr;30(4):351-363. doi: 10.1080/13543784.2021.1868437. Epub 2020 Dec 31.
3
Combination therapy of dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer.
Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):506-507. doi: 10.1016/j.hbpd.2020.12.010. Epub 2020 Dec 9.
4
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):483-485. doi: 10.1080/17474124.2021.1864325. Epub 2020 Dec 18.
5
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
Expert Opin Investig Drugs. 2021 Apr;30(4):309-316. doi: 10.1080/13543784.2021.1864320. Epub 2021 Jan 4.
6
The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
Expert Opin Investig Drugs. 2021 Apr;30(4):281-284. doi: 10.1080/13543784.2021.1849139. Epub 2020 Nov 23.
7
Recent advances of immunotherapy for biliary tract cancer.
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8.
8
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Expert Opin Investig Drugs. 2021 Apr;30(4):317-324. doi: 10.1080/13543784.2021.1837774. Epub 2020 Oct 25.
9
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?
ESMO Open. 2020 Sep;5(5):e001042. doi: 10.1136/esmoopen-2020-001042.
10
FGFR inhibitors in cholangiocarcinoma: what's now and what's next?
Ther Adv Med Oncol. 2020 Sep 16;12:1758835920953293. doi: 10.1177/1758835920953293. eCollection 2020.
Zotero 插件